Documents

A list of downloadable documents created during development.

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): equality impact assessment - guidance development

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): final appraisal determination

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): EIA form (scoping)

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): appraisal consultation

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): assessment report

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): letter to Consultees and Commentators regarding the Committee's request for additional analyses

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): final protocol

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): final matrix

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): final scope

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): response to comments on the provisional matrix

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): response to comments on the draft scope

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): draft scope

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): provisional matrix